Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow...

por Coudert, Bruno, Pierga, Jean-Yves, Mouret-Reynier, Marie-Ange, Kerrou, Kaldoun, Ferrero, Jean-Marc, Petit, Thierry, Du, Fanny Le, Dupré, Pierre-François, Bachelot, Thomas, Gabelle, Philippe, Chauvet, Marie-Pierre, Coeffic, David, Barbe, Catherine, Prevost, Jean-Briac, Paintaud, Gilles, Thibault, Gilles, Ferhat, Abdennour, Dupin, Julien, Berriolo-Riedinger, Alina, Arnould, Laurent
Publicado 2020